Shanghai Si Dan Race BioTechnology

Innovative Cellular Therapeutics (ICT), also known as Shanghai Sidanrace Biotechnology, is a clinical-stage biotechnology company focused on developing next-generation chimeric antigen receptor (CAR) T-cell therapies for both hematological malignancies and solid tumors. The company utilizes its proprietary CoupledCAR platform technology, which is designed to enhance the expansion and infiltration of CAR-T cells into solid tumors, addressing a major challenge in the field. Their lead candidate, ICTCAR014, is a next-generation CD19-targeting CAR-T therapy being evaluated for B-cell lymphomas. Additionally, ICT is advancing a pipeline of candidates targeting solid tumors, including colorectal cancer and liver cancer, with a focus on improving efficacy and safety in difficult-to-treat indications.